Clinical effects and medication regimen of adagrasib (Krazati) in patients with newly treated lung cancer

As of2025, Adagrasib (Adagrasib, trade name Krazati) as a targetKRAS G12Cmutated non-small cell lung cancer (NSCLC) drugs have shown good efficacy and safety in newly treated patients.

In the KRYSTAL-7 study, adagrasib was combined with pembrolizumab (Pembrolizumab, brand nameKeytruda) for treatment-naive KRAS Patients with G12CmutationsNSCLC have shown excellent efficacy. The study included 150 patients and showed that the objective response rate (ORR) in the combination treatment group was 5 9%, and the median progression-free survival (PFS) is 27.7 months, which is significantly better than traditional chemotherapy regimens.

The recommended dose of adagrasiib is600 mg taken orally twice daily. This dose has been proven to have good efficacy and acceptable safety in the KRYSTAL-1 study. In the KRYSTAL-7 study, patients received adagrasib 400 mg twice daily in combination with pembrolizumab 200 mg once every three weeks, showing excellent efficacy.

In theKRYSTAL-7 study, the safety profile of adagrasib combined with pembrolizumab was good. The incidence of treatment-related adverse events (TRAEs) was 95%, most of which were grade 1 or grade 2 and could be managed through dose adjustment or symptomatic treatment. Only a minority of patients required discontinuation of treatment due to adverse events.

Adagrasiib combined with pembrolizumab for initial treatmentKRAS G12CMutationNSCLC provides new treatment options for patients. When selecting a treatment option, factors such as the patient's PD-L1 expression level, previous treatment history, and comorbidities should be considered. For patients with PD-L1 expression ≥50%, the efficacy of adagrasib combined with pembrolizumab is more significant.

Reference link:https://www.drugs.com